{"id":781203,"date":"2023-08-31T03:03:03","date_gmt":"2023-08-31T07:03:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/"},"modified":"2023-08-31T03:03:03","modified_gmt":"2023-08-31T07:03:03","slug":"twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/","title":{"rendered":"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases"},"content":{"rendered":"

<\/p>\n

Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases<\/b><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE<\/a>)–Twist Bioscience Corporation<\/a> (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a drug discovery agreement with Ono Pharmaceutical Co.<\/a>, Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; \u201cOno\u201d) to discover and develop novel antibodies for the treatment of autoimmune diseases.<\/p>\n

\n\u201cOno has a strong and proven track record in developing antibody candidates in areas of need, including the development of the anti-PD-1 antibody Opdivo, which has had a tremendous impact for patients and researchers,\u201d said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. \u201cThis collaboration bringing together our antibody discovery expertise with Ono\u2019s experience in drug development has the potential to lead to future breakthrough treatment options for patients with autoimmune diseases.\u201d<\/p>\n

\nUnder the terms of the agreement, Twist will utilize the Twist Biopharma Solutions Library of Libraries to conduct research activities to discover novel antibodies against targets identified by Ono. Twist\u2019s Library of Libraries is an expansive collection of synthesized antibody libraries based on naturally occurring sequences that harness innovative structural and developability features to cover a wide range of drug targets. Twist will receive research fees, success-based clinical and regulatory milestones, as well as royalties on product sales. As part of the strategic collaboration, Ono will also utilize the scientific expertise of the Biopharma Solutions team and Twist\u2019s Premium Project Management services to evaluate new targets and generate comprehensive discovery campaigns. Ono will be responsible for the development, manufacturing and commercialization of any products resulting from the collaboration.<\/p>\n

\n\u201cWe are actively working to create biologics like antibodies in order to address unmet medical needs for a wide range of diseases including autoimmune diseases. We are very pleased to collaborate with Twist at this time in the area of autoimmune diseases and are confident that their expertise in antibody discovery and their impressive collection of diverse and highly specific antibody libraries will bring us potential functional antibodies,\u201d said Dr. Toichi Takino, Senior Executive Officer \/ Executive Director, Discovery and Research of Ono. \u201cWe believe that this new collaboration will enhance our biologics drug discovery efforts and bring innovative drugs for patients as soon as possible.\u201d<\/p>\n

About Ono Pharmaceutical Co., Ltd.<\/b><\/p>\n

\nOno Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company\u2019s website at https:\/\/www.ono-pharma.com\/en<\/a>.<\/p>\n

About Twist Biopharma Solutions (The Biologics Discovery and Optimization Division of Twist Bioscience)<\/b><\/p>\n

\nTwist Biopharma Solutions combines high-throughput DNA synthesis technology, deep expertise in antibody engineering and in vivo, in vitro and in silico discovery methods to provide end-to-end antibody discovery solutions across the preclinical continuum and tailored to our partner\u2019s specific needs. By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries with discovery beginning with either in vivo or in vitro diversity. Our Library of Libraries gives our partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development. Additionally, in vivo discovery approaches including single B cell screening and hybridoma discovery enable parallel paths where multiple technology methods can be leveraged to create a panel of highly diverse antibody leads. Our automated screening and panning processes enable us to identify high affinity leads that our partners can move forward into the clinic. We also offer supporting development capabilities, including IgG conversion, expression, purification, biophysical characterization, and functional characterization.<\/p>\n

\nFor more information visit: https:\/\/www.twistbioscience.com\/products\/antibody-discovery\/twist-bioscience-and-abveris<\/a><\/p>\n

About Twist Bioscience Corporation<\/b><\/p>\n

\nTwist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by \u201cwriting\u201d DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.<\/p>\n

\nFollow us on Twitter<\/a> | Facebook<\/a> | LinkedIn<\/a> | YouTube<\/a><\/p>\n

Twist Bioscience Legal Notice Regarding Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including, but not limited to, statements regarding the potential success of the collaboration and the achievement of any clinical or regulatory milestones or product sales, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience\u2019s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience\u2019s workforce reduction, transition of production to the Factory of the Future and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience\u2019s patents or proprietary rights; and the risk that Twist Bioscience\u2019s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience\u2019s business in general, see Twist Bioscience\u2019s risk factors set forth in Twist Bioscience\u2019s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230831082228\/en\/<\/a><\/span><\/p>\n

For Twist Bioscience:
\n<\/b>
Angela Bitting
\n
SVP, Corporate Affairs
\n
925-202-6211
\n
abitting@twistbioscience.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States Japan North America Asia Pacific<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Genetics Research Pharmaceutical Science Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a drug discovery agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; \u201cOno\u201d) to discover and develop novel antibodies for the treatment of autoimmune diseases. \u201cOno has a strong and proven track record in developing antibody candidates in areas of need, including the development of the anti-PD-1 antibody Opdivo, which has had a tremendous impact for patients and researchers,\u201d said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. \u201cThis collaboration bringing … <\/p>\n

Continue reading “Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781203","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTwist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a drug discovery agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; \u201cOno\u201d) to discover and develop novel antibodies for the treatment of autoimmune diseases. \u201cOno has a strong and proven track record in developing antibody candidates in areas of need, including the development of the anti-PD-1 antibody Opdivo, which has had a tremendous impact for patients and researchers,\u201d said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. \u201cThis collaboration bringing … Continue reading "Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-31T07:03:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230831082228r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases\",\"datePublished\":\"2023-08-31T07:03:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\\\/\"},\"wordCount\":1244,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230831082228r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\\\/\",\"name\":\"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230831082228r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-08-31T07:03:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230831082228r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230831082228r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases - Market Newsdesk","og_description":"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a drug discovery agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; \u201cOno\u201d) to discover and develop novel antibodies for the treatment of autoimmune diseases. \u201cOno has a strong and proven track record in developing antibody candidates in areas of need, including the development of the anti-PD-1 antibody Opdivo, which has had a tremendous impact for patients and researchers,\u201d said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. \u201cThis collaboration bringing … Continue reading \"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-31T07:03:03+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230831082228r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases","datePublished":"2023-08-31T07:03:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/"},"wordCount":1244,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230831082228r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/","name":"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230831082228r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-08-31T07:03:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230831082228r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230831082228r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/twist-bioscience-enters-into-agreement-with-ono-pharmaceutical-to-discover-novel-antibodies-for-autoimmune-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781203"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781203\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}